– UK, Cambridge – Dunad Therapeutics, a biopharmaceutical company developing covalent small molecule therapies with a focus on protein degradation, today announced the appointment of Michael Bonney as Chair of its Board of Directors, bringing more than 30 years of life sciences industry leadership experience, including serving as CEO of Cubist Pharmaceuticals and Executive Chair of Alnylam Pharmaceuticals.
“Michael’s background, expertise, and successful leadership in guiding biopharmaceutical companies through critical milestones will be of tremendous value as we grow Dunad and advance our therapies to become leaders in the covalent therapeutics and targeted protein degradation space. His deep experience with executive and leadership development, particularly for therapeutics companies with emerging, cutting-edge modalities, will be a guiding force for myself and other members of our executive team,” said CEO, Pearl Huang.
About Michael Bonney
His experience includes leading Cubist Pharmaceuticals to become the world’s leading antibacterial company before being purchased by Merck in January 2015 for $9.6b. Mr. Bonney was also VP of Sales and Marketing for Biogen, where he built the organization’s first commercial capability in the U.S. and launched Avonex, an injectable immunomodulator therapy for multiple sclerosis. More recently, Mr. Bonney held the position of CEO and Chair of Kaleido Biosciences, a company focused on developing microbiome therapies. In addition to Alnylam, Mr. Bonney has served as Board Chair of Magenta Therapeutics and Director of several biopharma companies including Sarepta Therapeutics, Bristol Myers Squibb, Celgene, and Syros Pharmaceuticals.
“Dunad’s unique small molecule platform has the potential to develop covalent therapeutics for protein degradation that can broadly address several disease areas, which inspired my decision to join as Chair of the board,” said Michael Bonney. “I am eager to work with Dunad’s impressive leadership team to overcome historic challenges in the field and advance therapies for previously undruggable targets.”
About Dunad Therapeutics
Dunad Therapeutics is a biopharmaceutical company with operations in Cambridge, England, and Cambridge, Massachusetts developing covalent small molecule therapies based on novel insights from chemistry and protein degradation. Dunad’s proprietary, the tunable platform is designed to discover and develop orally bioavailable, including CNS-accessible, therapeutics that have greater specificity and improved pharmacologic attributes compared with current therapies.
For more information: https://www.dunadtx.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
